SciSparc Ltd.

SPRC
About the company

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.

Country: IsraelPrice: $0.35Market Cap: $869,843

Investment snapshot

18%positive consensus
Scored 1d ago

Positive

3

BUY / PASS

Neutral / negative

3 / 10

NEUTRAL / FAIL

Median fair value

$80.38

+22670.5% vs price

Models with upside

4 / 17

Positive margin of safety

Strongest signal

SPRC undervalued: all 4 models price fair value above $0.35 (median $80.38)

Key risk

No clean pass — all 8 investors flag at least one growth criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictPASSFAILFAILNot rankedFAILFAILNEUTRALNEUTRALFAILFAILFAILBUYFAILFAILFAILBUYNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of Safety+92.4%N/AN/AN/AN/A+99.8%N/AN/A+95.6%N/AN/A+99.9%N/AN/AN/AN/AN/A
Financial Basis

Annual history · FY 2024

Latest source filing: 2025-04-24

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-24

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-24

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-24

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-24

Score computed: 2026-11-14

Annual history · FY 2024 · Market data at 2026-11-01

Latest source filing: 2025-04-24

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2024

Latest source filing: 2025-04-24

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2024

Latest source filing: 2025-04-24

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment

Latest source filing: 2025-04-24

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment

Latest source filing: 2025-04-24

Score computed: 2026-11-14

Annual history · FY 2024 · Market data at 2026-11-01

Latest source filing: 2025-04-24

Score computed: 2026-11-14

Annual history · FY 2024 · Price history 2025-01-01–2026-11-01

Latest source filing: 2025-04-24

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment

Latest source filing: 2025-04-24

Score computed: 2026-11-14

Annual history · FY 2024 · Price history 2025-01-01–2026-11-01

Latest source filing: 2025-04-24

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-24

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-04-24

Score computed: 2026-11-14

Annual history · FY 2024 · Price history 2025-01-01–2026-11-01

Latest source filing: 2025-04-24

Score computed: 2026-11-14

Where It Passes

  • Valuation models100% pass✓ 4▾

    SPRC undervalued: all 4 models price fair value above $0.35 (median $80.38)

    Graham fair value$4.66
    ✓Graham+92.4% margin vs $0.35
    Dreman fair value$152.65
    ✓Dreman+99.8% margin vs $0.35
    Akre fair value$8.11
    ✓Akre+95.6% margin vs $0.35
    Templeton fair value$312.66
    ✓Templeton+99.9% margin vs $0.35
  • Debt & Leverage67% pass✓ 11✗ 4▾

    8 of 12 pass — Graham, Buffett, Lynch +1 more object

    LT Debt vs Net Current Assets
    ✗GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 0.01, IC: -20.7x
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0.01
    ✓Lynch< 0.33
    Cash - Long-term Debt
    ✗LynchPositive preferred
    LT Debt / Total Assets Change0.00% -> 0.00%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities5.36
    ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0.01
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Debt Levels0.01
    ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=-20.7x, D/EBITDA=N/A
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0.01
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.0059; #523/4210 (top 12.4%)
    ✓AsnessTop 30% of eligible cross-section

Where It Falls Short

  • Growth0% pass✓ 2✗ 11▾

    No clean pass — all 8 investors flag at least one growth criterion

    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: -84.8% vs Rev: -54.6%
    ✓LynchInventory growth < Revenue growth
    EPS Growth Direction
    ✗DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency6/10 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth29.5%
    ✓Ackman>= 5%
    Positive EPS Growth Frequency
    ✗AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 76.1% -> 38.7%, operating margin -615.2% -> -560.2%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR
    ✗SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
  • Cash Flow10% pass✓ 2✗ 10▾

    9 of 10 flag SPRC's cash flow — Buffett, Lynch, Piotroski +6 more

    Free Cash Flow Proxy$-2.4M
    ✗BuffettPositive and growing
    FCF Positive and Growing$-7.9M
    ✗LynchPositive and growing
    Operating Cash Flow$-5.1M
    ✗PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=-49.33%, ROA=-60.73%
    ✓PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    P/E or FCF YieldP/E=0.3x
    ✓PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive0/7 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap
    ✗Ackman>= 4%
    Price / FCF per Share
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency0/10 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures
    ✗Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization
    ✗OshaughnessyTop 10% of eligible cross-section
  • Profitability13% pass✓ 5✗ 30▾

    14 of 16 flag SPRC's profitability — Graham, Buffett, Lynch +11 more

    Positive EPS (10 years)10/11 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)6/11 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-1.7%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)
    ✗BuffettStable or rising over 10 years
    Free Cash Flow Proxy$-2.4M
    ✗BuffettPositive and growing
    Earnings Variance (10-yr CoV)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE-77.1%
    ✗Lynch> 15%
    EBIT / Enterprise ValueN/A (EV <= 0)
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=N/A (EV <= 0), ROC=-450.8%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets-60.73%
    ✗PiotroskiROA > 0
    ROA Change YoY-45.81% -> -60.73% (delta: -14.93%)
    ✗PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=-49.33%, ROA=-60.73%
    ✓PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY76.3% -> 38.7%
    ✗PiotroskiImproved YoY
    Pre-Tax Income / Revenue-573.2%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity-77.1%
    ✗Dreman> 12%
    Margin of SafetyP/E=0.3x, P/B=0.5x
    ✓PabraiP/B < 1.5 or P/E < 15
    Return on Equity-61.5% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic Value99.8% (IV=$152.65 vs Price=$0.35)
    ✓Marks>= 20% below intrinsic value
    Positive Net Income Frequency6/10 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue-560.2%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity-77.1%
    ✗Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-615.2% (2022) -> -560.2% (2024)
    ✓TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 76.1% -> 38.7%, operating margin -615.2% -> -560.2%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization-722.43%; #6001/6340 (top 94.7%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+4.89%; #3103/3702 (top 83.8%)
    ✗AsnessTop 30% of eligible cross-section
    Net income / positive book equity-77.07%; #4459/5226 (top 85.3%)
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.7526; #5159/5884 (top 87.7%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years10/10 years positive
    ✓Schloss>= 70% positive over 5-10 observed years (app rule)
  • Verdicts23% pass✓ 3✗ 10▾

    Split decision: 10 FAIL · 3 NEUTRAL · 2 BUY · 1 PASS

    Overall verdict
    ✓GrahamPASS (4/9)✗BuffettFAIL (0/9)✗LynchFAIL (2/7)•GreenblattNot ranked✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (4/11)•MungerNEUTRAL (3/4)•PabraiNEUTRAL (2/3)✗AkreFAIL (1/6)✗MarksFAIL (2/5)✗AckmanFAIL (2/9)✓TempletonBUY (6/8)✗SleepFAIL (1/6)✗AsnessFAIL (Rank #2148/2370 (Top 90.6%))✗NeffFAIL (1/6)✓SchlossBUY (6/7)•OshaughnessyNEUTRAL (Not ranked)
  • Efficiency25% pass✓ 3✗ 8▾

    6 of 8 flag SPRC's efficiency — Buffett, Greenblatt, Piotroski +3 more

    Current Ratio5.36
    ✓Graham>= 2.0
    ROIC (3-5 yr avg)-483.1%
    ✗Buffett> 10%
    ROIC - WACC-493.1%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)-450.8%
    ✗Greenblatt> 25%
    Current Ratio Change YoY4.10 -> 5.36
    ✓PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY0.26x -> 0.13x
    ✗PiotroskiImproved YoY
    Current Assets / Current Liabilities5.36
    ✓Dreman> 1.5
    Return on Invested Capital-70.5%
    ✗Munger> 15%
    ROIC (high and growing)FY2022: ROIC=-101.1%; FY2023: ROIC=-70.0%; FY2024: ROIC=-70.5%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROICN/A (non-positive net income)
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/4 years above 12% (latest -70.5%)
    ✗SleepROIC > 12% in a majority of years
  • Valuation46% pass✓ 17✗ 11▾

    7 of 13 flag SPRC's valuation — Lynch, Greenblatt, Dreman +4 more

    Price / 3-yr avg EPS0.0x
    ✓Graham<= 15x
    Price-to-Book Ratio0.5x
    ✓Graham<= 1.5x
    P/E x P/B0.00
    ✓Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise ValueN/A (EV <= 0)
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=N/A (EV <= 0), ROC=-450.8%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS0.3x
    ✓Dreman< 12x✓Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    Price / Book Value per Share0.5x
    ✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)
    Valuation ReasonablenessP/E=0.3x, OE Yield=-151.8%
    ✓MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldP/E=0.3x
    ✓PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/E=0.3x, P/B=0.5x
    ✓MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic Value99.8% (IV=$152.65 vs Price=$0.35)
    ✓Marks>= 20% below intrinsic value
    Price / FCF per Share
    ✗Ackman<= 25
    Price vs. Trailing Low100% of trailing low ($0.35)
    ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization-722.43%; #6001/6340 (top 94.7%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+9.3741; #195/6449 (top 3.0%)
    ✓AsnessTop 30% of eligible cross-section
    Price / Diluted EPS0.3x
    ✓NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share0.57x
    ✓SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change+61430.1%
    ✓SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+1.5014; #1338/5247 (top 25.5%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date-88.79%; #5971/6202 (top 96.3%)
    ✗OshaughnessyTop 10% of eligible cross-section

Business & financials

Financial snapshot: annual FY 2024. Current investor scores may use newer quarterly data.

Company Profile

Industry: Pharmaceutical Products
SIC Sector: Chemicals & Pharmaceuticals
Size: Micro Cap($869,843)
Revenue: $1.3M-54.6% YoY
Net Income: $6.3M-22.7% YoY

Financial Snapshot

Operating Margin-560.2%
Return on Equity-77.1%
Debt / Equity0.01
Current Ratio5.36
EPS (Diluted)$1.28

Similar Companies

MRKMerck & Co., Inc.
$364.3B
ABTABBOTT LABORATORIES
$188.0B
BMYBRISTOL MYERS SQUIBB CO
$129.7B
TECHBIO-TECHNE Corp
$11.4B

Shareholder Return

Fiscal 2024

Share retirement not available for this company.

Buybacks
—
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

MetricFY 2024
Sources
  • 20-F · 2025-04-24
FY 2023
Sources
  • 20-F · 2024-04-01
FY 2022
Sources
  • 20-F · 2025-04-24
FY 2021
Sources
  • 20-F · 2022-04-28
FY 2020
Sources
  • 20-F · 2021-03-30
Market Cap$869.8Kcurrent--$30.1Best.$83.6Best.--
Revenue$1.3M↓55%$2.9M↑114%$1.3M----
Operating Income-$7.3M↓7%-$6.8M↑18%-$8.3M↓44%-$5.8M↓75%-$3.3M
Net Income-$6.3M↓23%-$5.1M↓98%-$2.6M↑55%-$5.8M↓264%$3.5M
EPS (Diluted)$1.28↓91%$14.43↓3%$14.82↓80%$73.58↑66791%$0.11
Gross Margin38.7%↓49%76.3%76.1%——
Operating Margin-560.2%↓137%-236.7%↑62%-615.2%——
ROE-77.1%↓15%-67.3%↓67%-40.2%↑43%-71.1%↓129%247.2%
Total Debt$48.0K↓37%$76.0K↑181%$27.0K↑50%$18.0K--
Shareholders' Equity$8.2M↑7%$7.6M↑18%$6.4M↓21%$8.1M↑469%$1.4M
Current Ratio5.36↑31%4.10↑278%1.09↓81%5.59↑148%2.25
Debt / Equity0.01↓41%0.01↑138%0.00↑89%0.00—
Operating Cash Flow-$5.1M↑13%-$5.9M↑26%-$7.9M↓56%-$5.1M↓18%-$4.3M
Free Cash Flow-----$7.9M↓56%-$5.1M--

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Pharmaceutical Products

SPRC vs Peers — Financial Grading

Revenue$1.3MBottom 25%
Net Income$6.3MMedian
ROE-77.1%Bottom 25%
D/E0.01Top 25%
Op. Margin-560.2%Bottom 25%
Curr. Ratio5.36Top 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11